AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17381964
Drug: Conjugated linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated linoleic acid (CLA) 3.9 g/d
Trial: 15200656
Drug: Rofecoxib 1
RxNorm normalized name: rofecoxib 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 1 mg x kg(‐1) (max 25 mg)
Trial: 8387191
Drug: Nedocromil (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedocromil (4 x 4 mg/d)
Trial: 3440107
Drug: Rectally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectally administered carbamazepine mixture
Trial: 3440107
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered carbamazepine mixture
Trial: 31888762
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg omega-3 fatty acid twice a day + vitamin D placebo every two weeks
Trial: 31888762
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid placebo twice a day + 50,000 IU vitamin D every two weeks
Trial: 31888762
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg omega-3 fatty acid twice a day + 50,000 IU vitamin D every two weeks
Trial: 31888762
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid placebo twice a day + vitamin D placebo every two weeks
Trial: 20072045
Drug: HMB +
RxNorm normalized name: Hydroxymethylbutyrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB + KIC (3 g.d HMB and 0.3 g.d KIC)
Trial: 20072045
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 g.d corn flour)
Trial: 17492341
Drug: Partly absorbable
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partly absorbable polypropylene-polyglactin mesh (Vypro II(R) 50 g/m(2), 79 hernias)
Trial: 17492341
Drug: Lightweight polypropylene
RxNorm normalized name: polypropylene (30000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lightweight polypropylene mesh (Premilene Mesh LP(R) 55 g/m(2), 75 hernias)
Trial: 17492341
Drug: Conventional densely
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional densely woven polypropylene mesh (Premilene(R) 82 g/m(2), 78 hernias)
Trial: 8681919
Drug: No‐treatment control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No‐treatment control condition
Trial: 2194652
Drug: Simultaneous infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous infusion of methotrexate and teniposide
Trial: 2194652
Drug: Sequential infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential infusion of methotrexate followed by teniposide
Trial: 26053503
Drug: Hydrophobic chlorhexidine‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrophobic chlorhexidine‐based gingiva‐adhering gel (applied once every second day for 14 days)
Trial: 26053503
Drug: 1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine water‐soluble gel (applied twice daily)
Trial: 16030082
Drug: Lumbar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar epidural corticosteroid injections (ESI) of triamcinolone acetonide, administered three times at intervals of 3 weeks.
Trial: 16030082
Drug: Interligamentous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interligamentous saline injections (placebo control), administered three times at intervals of 3 weeks.
Trial: 12042368
Drug: N(G)‐monomethyl‐L‐arginine (L‐NMMA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)‐monomethyl‐L‐arginine (L‐NMMA) (3 mg kg(‐1))
Trial: 31564317
Drug: Latanoprost administration
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost administration
Trial: 31564317
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of latanoprost
Trial: 23808222
Drug: Preoperative photodynamic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative photodynamic therapy (PhT) using chlorine E6 and light of wavelength 662 nm
Trial: 23808222
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without photodynamic therapy (PhT)
Trial: 23808222
Drug: Preoperative photodynamic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative photodynamic therapy (PhT)
Trial: 21920260
Drug: Biodegradable polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biodegradable polymer drug-eluting stents (n = 1,299)
Trial: 21920260
Drug: Permanent polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permanent polymer drug-eluting stents (n = 1,304)
Trial: 12177646
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy with > or =5 shocks
Trial: 9952095
Drug: Caffeine sodium
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine sodium benzoate (500 mg) in 1,000 mL normal saline
Trial: 9952095
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo) in 1,000 mL
Trial: 2259226
Drug: DA (daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA (daunorubicin 45 mg/m2/day x 3)
Trial: 2259226
Drug: MA (m-AMSA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MA (m-AMSA 200 mg/m2/day x 3 days)
Trial: 7402449
Drug: 1.2 mg
RxNorm normalized name: RNA 1.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg naloxone
Trial: 28192477
Drug: Early pharmacist-led
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early pharmacist-led medication review
Trial: 28192477
Drug: Early pharmacist-led
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early pharmacist-led medication review (for patients under 80 years)
Trial: 26486192
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo)
Trial: 24256460
Drug: Calcipotriol-betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcipotriol-betamethasone dipropionate ointment (CBD)
Trial: 23021506
Drug: PHiD-CV co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD-CV co-administered with routine childhood vaccines
Trial: 19782914
Drug: Selective inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective inhibitors of factor Xa and thrombin
Trial: 19782914
Drug: Conventional anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional anticoagulants (heparins and vitamin K antagonists)
Trial: 17313293
Drug: 6‐mg x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐mg x kg(‐1) dose of caffeine
Trial: 17313293
Drug: 3‐mg x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐mg x kg(‐1) dose of caffeine
Trial: 11677377
Drug: Valsartan +
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan + Hydrochlorothiazide (12.5 mg/day)
Trial: 11677377
Drug: Valsartan +
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan + Benazepril (10 mg/day)
Trial: 11677377
Drug: Valsartan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (80 mg/day) alone
Trial: 9674442
Drug: Anabolic steroids
RxNorm normalized name: ANABOLIC STEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anabolic steroids (250 mg testosterone i.m. at baseline and 12 mg oral stanozolol daily for 27 weeks)
Trial: 8023059
Drug: DFO (Deferoxamine)
RxNorm normalized name: DFO
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DFO (Deferoxamine) at a low dose of 10 mg/kg body weight per week
Trial: 24628437
Drug: Intra-pocket lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-pocket lidocaine and prilocaine gel (2.5% each)
Trial: 20488929
Drug: Subarachnoid morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid morphine (group SAM; n = 28)
Trial: 16146573
Drug: Implant supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant supported dentures
Trial: 10063488
Drug: Ethanol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.2 g/kg)
Trial: 7726267
Drug: Clotrimazole 100
RxNorm normalized name: clotrimazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 100 mg vaginal treatment for 7 days
Trial: 31035665
Drug: Low Amplitude
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Amplitude Seizure Therapy (LAP‐ST) at 500mA
Trial: 31035665
Drug: Standard Right
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Right Unilateral Electroconvulsive Therapy (RUL ECT) at 900 mA
Trial: 29111172
Drug: Nutritional counseling
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional counseling plus oral nutritional supplements (ONS)
Trial: 29111172
Drug: Nutritional counseling
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional counseling without oral nutritional supplements (ONS)
Trial: 25268205
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (cohort 1)
Trial: 25268205
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with a monoclonal antibody (cohort 2)
Trial: 22473458
Drug: Additional ARB
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional ARB therapy
Trial: 16223969
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy plus medical management for medication taper (CBT-MM)
Trial: 8957641
Drug: Barrier cream
RxNorm normalized name: Ceramax Skin Barrier Cream
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Barrier cream with particles
Trial: 8957641
Drug: Silicone-containing cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone-containing cream
Trial: 1349458
Drug: Propranolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (20 or 40 mg/day)
Trial: 1349458
Drug: Betaxolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol (10 or 20 mg/day)
Trial: 24051391
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% mixed with propofol formulations
Trial: 12492710
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of daclizumab (2 mg/kg)
Trial: 12492710
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of daclizumab (2nd dose, 1 mg/kg)
Trial: 12492710
Drug: Daclizumab levels
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab levels of 1 micro g/mL or greater
Trial: 1591091
Drug: Chemotherapy (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (six courses of cyclophosphamide, methotrexate and 5‐fluorouracil (CMF) followed by 4 courses of epirubicin)
Trial: 1591091
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chemotherapy and tamoxifen
Trial: 1591091
Drug: Concurrent or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent or sequential use of chemotherapy and tamoxifen
Trial: 30935324
Drug: Sham spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham spinal manipulative therapy (sham SMT)
Trial: 19650422
Drug: Burch suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Burch suspension
Trial: 15209619
Drug: Cisapride 5
RxNorm normalized name: cisapride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 5 mg orally three times daily for 12 weeks (dose doubled after 4 weeks if no improvement)
Trial: 15209619
Drug: Placebo three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times daily for 12 weeks (dose doubled after 4 weeks if no improvement)
Trial: 2731558
Drug: Full contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full contrast dose (282 mg I/kg body weight)
Trial: 2731558
Drug: Half contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half contrast dose (141 mg I/kg body weight)
Trial: 31295390
Drug: Manual toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrush with CrissCross and tapered bristle technology (Oral-B CrossAction Ultrathin); brushed twice daily for 4 weeks.
Trial: 31295390
Drug: Traditional flat-trim
RxNorm normalized name: phentermine hydrochloride Oral Capsule [Oby-Trim]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional flat-trim design and regular non-tapered bristles (Oral-B Indicator Soft 35); brushed twice daily for 4 weeks.
Trial: 19179885
Drug: Placebo (dilute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (dilute preparation of Pregestamil formula)
Trial: 14688021
Drug: Variant SULT1A1
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variant SULT1A1 genotype (638GA or AA) with cumulative smoking dose
Trial: 9331014
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (4-16 mg once-daily)
Trial: 21964277
Drug: Citalopram (flexible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (flexible doses) for up to 14 weeks
Trial: 19109962
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg) administered intravenously within 4 weeks of surgery and continued for 1 year
Trial: 10467830
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1000 mg/day for 3 months)
Trial: 2319316
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy with adjuvant chemotherapy (CCNU, vincristine, and prednisone)
Trial: 2319316
Drug: Chemotherapy (CCNU,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CCNU, vincristine, and prednisone) in patients with more extensive tumors
Trial: 2319316
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (radiation therapy with and without chemotherapy)
Trial: 536969
Drug: Bendrofluazide 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide 2.5 mg twice a day
Trial: 536969
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propranolol and bendrofluazide
Trial: 30651036
Drug: Udenafil 75
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil 75 mg daily
Trial: 31320603
Drug: Vacuum sealing
RxNorm normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum sealing drainage (VSD) treatment combined with skin flap transplantation and antibiotic bone cement
Trial: 25803642
Drug: Multivalent NoV
RxNorm normalized name: Dallergy Reformulated Nov 2011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivalent NoV VLP vaccine (genotypes GI.1/GII.4)
Trial: 28755607
Drug: Cabozantinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (100 mg daily)
Trial: 19565549
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment plus rheumatologic care program
Trial: 16782719
Drug: Adenosine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (50 or 70 microg/kg/min) for 3 hours starting within 15 minutes of reperfusion therapy
Trial: 15307977
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH), specifically dalteparin
Trial: 9124466
Drug: Ketoconazole (steroidogenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (steroidogenic enzyme inhibitor)
Trial: 8066317
Drug: Weekly replaced
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly replaced vinyl urinary drainage bags (group C)
Trial: 3113764
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) continuous infusion
Trial: 30604373
Drug: TELE‐IBD system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TELE‐IBD system (self-testing weekly)
Trial: 26538205
Drug: COX-2 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COX-2 + PPI (celecoxib 200 mg twice daily + rabeprazole 20 mg once daily)
Trial: 26538205
Drug: COX-2 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COX-2 + placebo (celecoxib 200 mg twice daily + placebo)
Trial: 24949820
Drug: As needed
RxNorm normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As needed treatment
Trial: 22130905
Drug: Relapse prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relapse prevention therapy (RPT)
Trial: 12482641
Drug: Control (diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (diet or metformin)
Trial: 8383397
Drug: Lisinopril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (2.5 mg o.d. initially, increased to 5 mg and 10 mg o.d.)
Trial: 8383397
Drug: Captopril (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (6.25 mg t.i.d. initially, increased to 12.5 mg and 25 mg t.i.d.)
Trial: 27340360
Drug: lafutidine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lafutidine (10 mg, twice daily)
Trial: 27340360
Drug: lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole (30 mg, once daily)
Trial: 23554851
Drug: Clonazepam 1
RxNorm normalized name: clonazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam 1 mg
Trial: 23554851
Drug: Tolterodine 1
RxNorm normalized name: tolterodine 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 1 mg (active placebo)
Trial: 23554851
Drug: Intramuscular pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular pain models
Trial: 20825071
Drug: Ranibizumab (Lucentis)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab (Lucentis) administered in doses of 0.3 or 0.5 mg into the vitreous body
Trial: 1931705
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b (IFN alpha-2b) with reduced doses
Trial: 6277355
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg delta 9THC
Trial: 6277355
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg delta 9THC
Trial: 6277355
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg delta 9THC
Trial: 31186121
Drug: 7-day ibuprofen
RxNorm normalized name: hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-day ibuprofen (600 mg three times a day)
Trial: 31186121
Drug: 3-day ibuprofen
RxNorm normalized name: ibuprofen 3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day ibuprofen (600 mg three times a day for 3 days, then placebo for 4 days)
Trial: 23686032
Drug: Motor complications
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor complications of PD therapy
Trial: 23686032
Drug: Dopaminergic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic medication profiles
Trial: 19121446
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blocker alone
Trial: 19121446
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blocker plus digoxin
Trial: 19121446
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no beta blocker or digoxin)